Smith Chas P & Associates PA Cpas Acquires 165,286 Shares of Novo Nordisk A/S $NVO

Smith Chas P & Associates PA Cpas increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 40.8% in the 4th quarter, Holdings Channel reports. The fund owned 570,711 shares of the company’s stock after buying an additional 165,286 shares during the quarter. Novo Nordisk A/S accounts for about 1.5% of Smith Chas P & Associates PA Cpas’ investment portfolio, making the stock its 28th biggest position. Smith Chas P & Associates PA Cpas’ holdings in Novo Nordisk A/S were worth $29,038,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of NVO. Revolve Wealth Partners LLC increased its stake in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after acquiring an additional 200 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after acquiring an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC increased its stake in shares of Novo Nordisk A/S by 18.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after acquiring an additional 1,587 shares in the last quarter. Invesco Ltd. increased its stake in shares of Novo Nordisk A/S by 26.3% in the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after acquiring an additional 87,467 shares in the last quarter. Finally, Gamco Investors INC. ET AL bought a new stake in Novo Nordisk A/S during the 2nd quarter valued at about $314,000. 11.54% of the stock is currently owned by institutional investors.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk is being highlighted as one of the more undervalued foreign stocks, with recent results showing a profit beat and a slightly raised full-year outlook, helped by early demand for its Wegovy weight-loss pill in the U.S. Novo Nordisk (NVO) Among Our Most Undervalued Foreign Stocks to Buy Now
• Positive Sentiment: The company announced new cardiometabolic pipeline data, including Phase 3 CagriSema results and additional abstracts for the ADA 2026 meeting, which could strengthen investor confidence in future obesity and diabetes growth drivers. Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions
• Positive Sentiment: Novo Nordisk is nearing EU approval for oral Wegovy, which could expand access, improve convenience, and support longer-term sales growth. Novo Nordisk Nears EU Nod For Oral Wegovy And Investor Opportunity
• Positive Sentiment: Management also launched a share repurchase program, a shareholder-friendly move that can help support the stock. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Several articles compared Novo Nordisk with Eli Lilly and Amgen, keeping attention on GLP-1 competition, pipeline depth, and valuation rather than pointing to any immediate fundamental shock. Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy?
• Negative Sentiment: Brazil approved the first generic copy of Ozempic, signaling new competition in a key growth category and adding pressure to Novo Nordisk’s pricing power. Brazil Clears First Generic Copy of Novo Nordisk’s Ozempic Shot
• Negative Sentiment: Broader healthcare weakness also weighed on the group, with the sector finishing lower in late trading, which may have added short-term pressure to NVO. Sector Update: Healthcare Stocks Decline Late Afternoon

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $44.59 on Thursday. The firm’s 50-day moving average price is $40.67 and its 200-day moving average price is $46.38. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The company has a market cap of $199.10 billion, a PE ratio of 10.47, a PEG ratio of 3.94 and a beta of 0.77. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The firm had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.46 EPS for the current year.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of analyst reports. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.